Volume 12, Issue 4 (Winter 2016)                   Sci J Iran Blood Transfus Organ 2016, 12(4): 388-393 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Chegini A. Therapeutic plasmapheresis in myasthenic crisis after botox injection. Sci J Iran Blood Transfus Organ 2016; 12 (4) :388-393
URL: http://bloodjournal.ir/article-1-882-en.html
Therapeutic plasmapheresis in myasthenic crisis after botox injection
A. Chegini *
Keywords: Key words: Blood Component Removal, Myasthenia Gravis, Botulinum Toxins
Full-Text [PDF 189 kb]   (3767 Downloads)     |   Abstract (HTML)  (6573 Views)
Full-Text:   (19343 Views)
References :  
  1. Pinching AJ, Peters DK. Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2(8000): 1373-6.
  2. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill Education; 2015. p. 2704-6.                           
  3. MCLeod BC, Weinstein R ,Winters JL. Textbook of apheresis principles and practice. 3rd ed. USA: AABB; 2010. p. 295-317.  
  4. King Karen E, Bandarenko N. Blood Transfusion therapy (a physician's handbook). 11th ed. USA: AABB; 2014. p. 217-24.                             
 
  1. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the apheresis applications committee of the American society for apheresis . J Clin Apher 2007; 22(3): 75-106.              
  2. Roback DJ, Combs MR, Grossman BJ, Hillyer Ch. Technical Manual. 6th ed. USA: AABB. p. 697-711.  
  3. Klein HG, Anstee DJ. Mollison’s Blood Transfusion in Clinical Medicine. 12th ed. 2014. p. 782-3.
  4. Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol 2010; 55(1): 8-14.                                                        
 
  1. Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol 1999; 38(9): 641-55.                            
  2. Giotzolou T, Cordivari C, Lee PJ, Hanna MG, Lees AJ. Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature. J Nourol Neurosurg Psychiatry 2005; 76(11): 1594-6.        
  3. Patel V, Elston J, Malhotra R. Prolonged effect of botulinum toxin-A treatment  in patients with Myastheina Gravis. Journal of Clinical & Experimental Ophthalmology 2011; 2: 3.                                           
  4. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61(12): 1652-61                                                   
  5. Romi F, Gihus NE, Aarli JA. Myasthenia  gravis: clinical,  immunological  and    therapeutic     advances.
Acta Neurol Scand 2005; 111(2): 134-41                                                                                                  
  1. Vincent A. Unravelling the pathogenesis of myasthenia   gravis. Nat  Rev Immunol 2002; 2(10): 797-804.                                                                                                        
  2. Richman DP, Wollmann RL, Maselli RA, Gomez CM, Corey AL, Agius MA, et al. Effector       mechanisms of myasthenic antibodies. Ann N Y Acad  Sci 1987; 681: 264-73.                                                                                                    
  3. Lindstrom JM, Seybold ME, Lenon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976 ;26(11): 1054-9.
  4. Seybold ME. Plasmapheresis in myasthenia gravis. Ann  NY Acad Sci 1987; 505: 584-7                                                                                    
 
  1. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppression drug therapy in myasthenia gravis. N Engl J Med 1977; 297(21): 1134-40                                                               
  2. Dau PC. Plasmapheresis therapy in Myasthenia gravis. Muscle Nerve 1980; 3(6): 468-82.
  3. Szczepiokowski  ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis  Applications Committee of American Society for Apheresis. J Clin Apher 2010; 25(3): 83-177
  4. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur  J Neurol 2006; 13(7): 691-9.
  5. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol 1994; 97 Suppl 1: 49-51.
  6. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous  immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41(6): 789-96.
  7. Qureshi AI, Chodhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al. Plasma exchange versus in intravenous immunoglobulin treatment in myasthenia crisis. Neurology 1999; 52(3): 629-52.
 
 
 
 
 
 
 

 
 
 
 
Sci J Iran Blood Transfus Organ 2016; 12(4): 388-393
 
Case Report
 
 

Therapeutic plasmapheresis in myasthenic 
crisis after botox injection
 
Chegini A.1
 
 
 
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
 
 
Abstract
Background and Objectives
Botox decreases wrinkles in face and chin. This drug minimizes muscle activity with its side effects being rare. This article presents one of this rare cases.
 
Case
A 30-year-old woman with petosis, diplopia, dysartheria, dysphagia and muscle weakness was admitted to the hospital. She had no history of disease. She had three Botox injections during the preceding month. In the examination, muscle weakness 4/5 (cervical extensor, ocular and pharynx) was detected. Her diagnosis was myasthenia gravis. With TPE, force enhancement after muscle stretch was seen and she was separated from artificial ventilation.
 
Conclusions 
Myasthenia gravis is caused by antibody-acetylcholine receptor at the neuromuscular junction or motor end plate. Therapeutic plasmapheresis decreases the level of antibody-acetylcholine receptor.  
 
Key words: Blood Component Removal, Myasthenia Gravis, Botulinum Toxins                                                                                                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Received:  11 Jul 2014
Accepted: 24 Jun 2015
 
 
 
 

Correspondence: Chegini A., MD. Specialist in Anesthesiology. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052256; Fax: (+9821) 88601599
E-mail: a.chegini@ibto.ir
Type of Study: case report | Subject: Blood transfusion medicine
Published: 2016/01/6
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb